﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Pharmaceutical Sciences</JournalTitle>
      <Issn>1735-403X</Issn>
      <Volume>29</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2023</Year>
        <Month>07</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The Effects of Vitamin K2 (Menaquinone-7) on the Leptin and Adiponectin Levels in Overweight/Obese Type 2 Diabetes Patients: A Randomized Clinical Trial</ArticleTitle>
    <FirstPage>346</FirstPage>
    <LastPage>354</LastPage>
    <ELocationID EIdType="doi">10.34172/PS.2022.30</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Shaghayegh</FirstName>
        <LastName>Adeli</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-2273-1897</Identifier>
      </Author>
      <Author>
        <FirstName>Bahram</FirstName>
        <LastName>Pourghassem Gargari</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-7667-099X</Identifier>
      </Author>
      <Author>
        <FirstName>Nahid</FirstName>
        <LastName>Karamzad</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-1628-1348</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/PS.2022.30</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2022</Year>
        <Month>07</Month>
        <Day>02</Day>
      </PubDate>
    </History>
    <Abstract>Background: Type 2 diabetes mellitus (T2DM) is a prevalent disease with metabolic consequences. Lower levels of adiponectin and higher levels of leptin were reported in T2DM. This study aimed to evaluate the effect of menaquinone-7 (MK-7) supplementation on adiponectin and leptin in overweight/obese T2DM patients.  Methods: Sixty men and women with T2DM and 27 ≤ body mass index &lt; 35 kg/m2 , participated in this double-blind placebo-controlled randomized clinical trial for 12 weeks. The subjects were allocated into intervention (200 µg/day MK-7) or placebo groups. Three-day food records, anthropometrics and physical activity were assessed and fasting blood samples were collected at the pre- and post-intervention. Serum adiponectin, leptin, fasting blood sugar (FBS) and fasting insulin (FI) were measured and adiponectin to leptin ratio (A/L ratio) was calculated.  Results: MK-7 decreased fasting blood sugar (P: 0.018) and fasting insulin (P: 0.012), according to a within group analysis of the 45 patients who finished the research. Fasting blood sugar (P: 0.024) and leptin levels (P: 0.032) were lower in the MK-7 group, but there were no significant changes between the groups in terms of adiponectin or the adiponectin to leptin (A/L) ratio.  Conclusion: Current study showed that MK-7 supplementation could lead to significant reduction in leptin and FBS, but it has no effect on the adiponectin and A/L ratio in overweight/ obese T2DM patients. </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Adiponectin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Diabetes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Leptin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Menaquinone-7</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Obesity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Overweight</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>